Jazz Q2 FY26 GAAP EPS rises 16% to $2.78; revenue increases 16% to $1.21 billion
JAZZ•Quarterly results
- Jazz Pharmaceuticals posted 2Q26 revenue of $1.21 billion, up 16% year over year, as GAAP net income swung to $192.8 million.
- GAAP diluted EPS was $2.78; non-GAAP adjusted EPS was $5.71.
Product revenue and guidance
- Xywav revenue rose 13% to $471.2 million; Epidiolex/Epidyolex climbed 16% to $292.1 million.
- Zepzelca revenue increased 42% to $105.8 million; Modeyso delivered $48.2 million in revenue.
- 2026 revenue guidance was raised to $4.6 billion-$4.75 billion from $4.25 billion-$4.5 billion.
